lilly oral glp 1 A new class of GLP-1 that works differently than oral semaglutide just got one step closer to FDA approval. Eli released new Phase 3 data on orforglipron. Swipe to learn The Food and Drug Administration

HealthGAINS will continue to monitor patients throughout their therapy to make adjustments as needed and ensure the plan is working for them

It is very interesting that mercury, and only mercury, has a significant negative correlation with RBC glutathione, and again suggests the special importance and toxicity of mercury

We'll be watching closely to see how the FDA weighs the available science and what these recommendations could meannot just for compounding, but for the future of regenerative medicine and military healthcare

Global demand surged after widespread coverage and endorsements, framing them as shortcuts rather than medical interventions